Lockhart Pauline, Daly Fergus, Pitkethly Marie, Comerford Natalia, Sullivan Frank
Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, UK, DD2 4BF.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD001869. doi: 10.1002/14651858.CD001869.pub4.
Antiviral agents against herpes simplex virus are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but their effectiveness is uncertain. Significant morbidity can be associated with severe cases.
This review addresses the effect of antiviral therapy on Bell's palsy.
We updated the search of the Cochrane Neuromuscular Disease Group Trials Register (December 2008), MEDLINE (from January 1966 to December 8 2008), EMBASE (from January 1980 to December 8 2008) and LILACS (from January 1982 to December 2008).
Randomized trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy.
Twenty-three papers were selected for consideration.
Seven trials including 1987 participants met the inclusion criteria, adding five studies to the two in the previous review.Incomplete recovery at one year. There was no significant benefit in the rate of incomplete recovery from antivirals compared with placebo (n = 1886, RR 0.88, 95% CI 0.65 to 1.18). In meta-analyses with some unexplained heterogeneity, the outcome with antivirals was significantly worse than with corticosteroids (n = 768, RR 2.82, 95% CI 1.09 to 7.32) and the outcome with antivirals plus corticosteroids was significantly better than with placebo (n = 658, RR 0.56, 95% CI 0.41 to 0.76).Motor synkinesis or crocodile tears at one year. In single trials, there was no significant difference in long term sequelae comparing antivirals and corticosteroids with corticosteroids alone (n = 99, RR 0.39, 95% CI 0.14 to 1.07) or antivirals with corticosteroids (n = 101, RR 1.03, 95% CI 0.51 to 2.07).Adverse events.There was no significant difference in rates of adverse events between antivirals and placebo (n = 1544, RR 1.06, 95% CI 0.81 to 1.38), between antivirals and corticosteroids (n = 667, RR 0.96, 95% CI 0.65 to 1.41) or between the antiviral-corticosteroid combination and placebo (n = 658, RR 1.15, 95% CI 0.79 to 1.66).
AUTHORS' CONCLUSIONS: High quality evidence showed no significant benefit from anti-herpes simplex antivirals compared with placebo in producing complete recovery from Bell's palsy. Moderate quality evidence showed that antivirals were significantly less likely than corticosteroids to produce complete recovery.
抗单纯疱疹病毒药物广泛用于特发性面神经麻痹(贝尔麻痹)的治疗,但其疗效尚不确定。严重病例可能伴有显著的发病率。
本综述探讨抗病毒治疗对贝尔麻痹的影响。
我们更新了对Cochrane神经肌肉疾病组试验注册库(2008年12月)、MEDLINE(1966年1月至2008年12月8日)、EMBASE(1980年1月至2008年12月8日)和LILACS(1982年1月至2008年12月)的检索。
抗病毒药物联合或不联合皮质类固醇与对照疗法治疗贝尔麻痹的随机试验。
选择23篇论文进行审议。
7项试验(共1987名参与者)符合纳入标准,在前次综述中的2项研究基础上增加了5项研究。一年时未完全恢复。与安慰剂相比,抗病毒药物在未完全恢复率方面无显著益处(n = 1886,RR 0.88,95%CI 0.65至1.18)。在存在一些无法解释的异质性的荟萃分析中,抗病毒药物的结果显著差于皮质类固醇(n = 768,RR 2.82,95%CI 1.09至7.32),而抗病毒药物加皮质类固醇的结果显著优于安慰剂(n = 658,RR 0.56,95%CI 0.41至0.76)。一年时的联动或鳄鱼泪。在单项试验中,将抗病毒药物和皮质类固醇与单独使用皮质类固醇相比(n = 99,RR 0.39,95%CI 0.14至1.07),或将抗病毒药物与皮质类固醇相比(n = 101,RR 1.03,95%CI 0.51至2.07),长期后遗症方面无显著差异。不良事件。抗病毒药物与安慰剂之间(n = 1544,RR 1.06,95%CI 0.81至1.38)、抗病毒药物与皮质类固醇之间(n = 667,RR 0.96,95%CI 0.65至1.41)或抗病毒 - 皮质类固醇联合用药与安慰剂之间(n = 658,RR 1.15,95%CI 0.79至1.66)的不良事件发生率无显著差异。
高质量证据表明,与安慰剂相比,抗单纯疱疹病毒药物在使贝尔麻痹完全恢复方面无显著益处。中等质量证据表明,抗病毒药物完全恢复的可能性显著低于皮质类固醇。